Previous Article | Next Article 
Infection and Immunity, November 1999, p. 6203-6205, Vol. 67, No. 11
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Inhibition of Neutrophil Apoptosis by Verotoxin 2 Derived from Escherichia coli O157:H7
Jiajia
Liu,
Tohru
Akahoshi,*
Takeshi
Sasahana,
Hidero
Kitasato,
Rie
Namai,
Takeji
Sasaki,
Matsuhisa
Inoue, and
Hirobumi
Kondo
Department of Internal Medicine and
Microbiology, Kitasato University School of Medicine, Sagamihara,
Kanagawa 228-8555, Japan
Received 6 July 1999/Returned for modification 30 July
1999/Accepted 20 August 1999
 |
ABSTRACT |
In order to evaluate the pathological role of verotoxin 2 (VT2), we
investigated the effects of VT2 on neutrophil apoptosis in vitro. The
results showed that VT2 caused a significant delay in spontaneous
neutrophil apoptosis and that the effect was abrogated by a protein
kinase C inhibitor. These data indicate that longer survival of
neutrophils may aggravate neutrophil-mediated tissue damage in
VT2-associated diseases.
 |
TEXT |
Verotoxin (VT)-producing
Escherichia coli (VTEC) strains of serotype O157:H7 have
been implicated as causes of a wide spectrum of diseases, ranging from
bloody diarrhea and hemorrhagic colitis to hemolytic uremic
syndrome. A number of studies have shown that production of VTs from
VTEC O157:H7 has an essential role in these diseases (1, 3,
5, 10). Two serologically distinct VTs from this microorganism,
VT1 and VT2, have been identified. Biological and physical analysis has
demonstrated that VT1 and VT2 share biological activities and receptor
specificities (7, 19). Infiltration of neutrophils at the
inflamed site of VTEC-associated diseases has been well documented, and
recent studies suggest an essential role of neutrophils in the
pathogenesis of these diseases (4, 5, 13). Neutrophils have
the shortest life span among circulating leukocytes. Senescent
neutrophils rapidly die, exhibiting the characteristic morphological
changes indicative of programmed cell death, or apoptosis. Neutrophils
undergoing apoptosis lose their functions and are sequestered from the
inflammatory site through phagocytosis by macrophages (2,
17). Therefore, apoptosis may be an important mechanism for
regulating the balance between host defense and neutrophil-mediated
tissue injury. However, the regulatory effects of VTs on neutrophil
apoptosis remain unknown. Thus, we conducted the present study to
investigate the effect of VT2 on neutrophil apoptosis.
Inhibition of spontaneous neutrophil apoptosis by VT2.
VT2 was
purified from VTEC O157:H7 strain KSE-1571 by cation-exchange
chromatography and high-performance liquid chromatography (11). Contamination by lipopolysaccharide (LPS) in the
preparation of VT2 was determined to be less than 0.03 EU/ml by
Limulus amebocyte lysate assay. Heparinized peripheral blood
was obtained from healthy volunteers, and neutrophils were isolated by
3% dextran sedimentation followed by density gradient centrifugation
with Ficoll-Paque. In order to determine whether or not VT2 affects
spontaneous neutrophil apoptosis, neutrophils (2 × 106 cells) were incubated with culture medium (RPMI 1640, 10% fetal calf serum) containing purified VT2 for 24 h.
Subsequently, cells were treated with hypotonic fluorochrome solution
(100 µg of propidium iodide per ml in 0.1% sodium citrate and 0.1%
Triton X-100) and stored overnight at 4°C. The fluorescence intensity
of each individual nucleus was determined by a FACScan flow cytometer
(14). As shown in Fig. 1A, 74% of the cells underwent
apoptosis spontaneously following 24 h of incubation, which is
consistent with previous reports (15, 20). The
apoptotic responses of neutrophils were apparently inhibited by
VT2 in a dose-dependent manner. Figure 1B
illustrates the time kinetics of the effect of purified VT2 on
spontaneous neutrophil apoptosis. Cells were incubated with 0.1 U of VT2 per ml at 37°C for up to 48 h. Purified VT2
significantly prevented spontaneous neutrophil apoptosis in a
time-dependent manner. Morphological evaluation of cultured neutrophils
also revealed an apparent inhibition of spontaneous neutrophil
apoptosis by VT2 (data not shown).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of VT2 on neutrophil apoptosis. (A)
Neutrophils (2 × 106 cells) were incubated in
triplicate with varying concentrations of VT2 ( ) for 24 h. (B)
Neutrophils were incubated with medium alone ( ) or with 0.1 U of VT2
per ml ( ) for the periods indicated. Cells were subsequently
harvested, and cellular apoptosis was determined by flow
cytometric analysis. Data are shown as percentages of apoptotic
cells; they represent the means and indicated standard deviations of a
representative experiment. These results were confirmed in six separate
experiments performed with neutrophils isolated from independent
donors. Asterisks represent P values of <0.01 compared with
controls.
|
|
DNA fragmentation.
The VT2-induced delay in neutrophil
apoptosis was verified by confirming DNA fragmentation.
Neutrophils (7 × 106 cells) were incubated with 400 µl of cold hypotonic lysing buffer (10 mM Tris-HCl [pH 7.5], 1 mM
EDTA, and 0.2% Triton X-100) for 20 min on ice, and the lysate was
centrifuged. Low-molecular-weight DNA in the supernatant was obtained
by phenol extraction. After digesting with RNase, the samples were
electrophoresed in a 1% agarose gel and stained with ethidium bromide.
As shown in Fig. 2, neutrophils incubated
with medium alone for 24 h demonstrated an increased amount of
low-molecular-weight DNA, which was electrophoresed in a dense ladder
pattern. Neutrophils incubated with 0.1 U of VT2 per ml exhibited
low-molecular-weight DNA in lesser quantities without exhibiting a
ladder formation.

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 2.
Agarose gel electrophoresis of low-molecular-weight DNA.
Neutrophils were incubated with medium alone (lane 2) or with 0.1 U of
VT2 per ml (lane 3) for 24 h. After treatment,
low-molecular-weight DNA of the neutrophils was detected by agarose gel
electrophoresis. The results are representative of three separate
experiments using neutrophils isolated from three different donors.
|
|
Elimination of VT2 by anti-VT2 antibody and heat inactivation.
Purified VT2 at a concentration of 0.02 U/ml was treated with latex
beads conjugated with anti-VT2 antibody (Denka Seiken, Tokyo, Japan).
This treatment caused a 57% reduction in Vero cell cytotoxic activity
of VT2. As shown in Table 1, treatment of VT2 with the antibody promoted a 38% reduction in the effect of VT2 on
neutrophil apoptosis (P < 0.01). LPS is well
known to be heat resistant, while VT2 is sensitive. Thus, purified VT2
(0.02 U/ml) was treated at 60°C for 15 min, and the inhibitory effect on neutrophil apoptosis was determined. Heat inactivation of
VT2 significantly abolished the effect of VT2 on neutrophil
apoptosis (P < 0.01). In order to confirm the
inhibitory effect of VT2 on neutrophil apoptosis, we evaluated
the biological effect of recombinant VT2 (rVT2) on neutrophil
apoptosis. rVT2 exerted verocytotoxic activity at 0.08 U/µg
of protein, and contamination by LPS was shown to be less than 1.2 × 10
5 EU/µg. As shown in Table 1, rVT2 at 0.1 U/ml
significantly inhibited spontaneous neutrophil apoptosis
(P < 0.01). These data indicate that the effect of VT2
on neutrophil apoptosis is LPS independent.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Effects of anti-VT2 antibody, heat treatment, and
metabolic inhibitors on the VT2-induced delay in
neutrophil apoptosis
|
|
Effects of metabolic inhibitors on the VT2-induced delay in
neutrophil apoptosis.
In order to evaluate the mechanisms
of VT2 action, neutrophils were incubated with VT2 (0.02 U/ml) for
24 h in the presence and absence of various metabolic inhibitors.
A potent inhibitor of protein kinase C (PKC), staurosporine at 100 nM,
significantly restored the inhibitory effect of VT2 (P < 0.01), indicating possible involvement of the PKC pathway in
VT2-treated cells (Table 1). In contrast, a tyrosine kinase inhibitor,
genystein at 50 µg/ml, and a selective inhibitor of protein kinase A,
H-89 at 20 µM, failed to prevent the effect of VT2.
Conclusions.
In the present study, we have provided evidence
for the first time that VT2 derived from E. coli O157:H7
inhibits spontaneous neutrophil apoptosis in a time- and
dose-dependent manner and that the PKC pathway may be involved in
VT2-treated cells.
VT was first identified as a cytotoxin for Vero cells (6, 8,
9). Subsequent studies have demonstrated that VTs are capable of
inducing cellular death in various types of cells (12, 21).
In contrast, the cytotoxic effect of VT1 on monocytes and macrophages
was negligible. Recent studies have shown that VT1 is capable of
stimulating macrophages or monocytes to produce various cytokines
(16, 18, 22). Increased production of proinflammatory
cytokines may contribute to the development of inflammatory
responses in VTEC-associated diseases. Based on this evidence and
the results of this study, it seems reasonable to suppose that VTs
exert stimulatory effects on inflammatory leukocytes and promote longer
survival through the prevention of apoptosis. The VT2-induced
delay in neutrophil apoptosis may enhance inflammation and
result in aggravation of neutrophil-mediated tissue damage in
VTEC-associated diseases. We have demonstrated that a
specific inhibitor of PKC abrogates the effect of VT2 on
neutrophil apoptosis. Although the activation of PKC in
VT2-treated neutrophils has not yet been directly demonstrated, our
results indicate that PKC may be involved in the VT2-induced delay in
neutrophil apoptosis.
Further investigation should be directed toward the in vivo effects of
VT2 on neutrophil apoptosis. Elucidation of the precise roles
of VTs in VTEC-associated diseases may provide therapeutic advantages
against these diseases.
 |
ACKNOWLEDGMENTS |
We thank Fumio Gondaira (Denka Seiken, Tokyo, Japan) for providing rVT2.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Internal Medicine and Microbiology, Kitasato University School of
Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan. Phone: 42-778-9347. Fax: 42-778-8441. E-mail:
akahoshi{at}med.kitasato-u.ac.jp.
Editor:
J. T. Barbieri
 |
REFERENCES |
| 1.
|
Argyle, J. C.,
R. T. Hogg,
T. J. Pysher,
F. G. Silva, and R. L. Siegler.
1990.
A clinicopathological study of 24 children with hemolytic uremic syndrome.
Pediatr. Nephrol.
4:52-58[Medline].
|
| 2.
|
Brach, M. A.,
S. deVos,
H.-J. Gruss, and F. Herrmann.
1992.
Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death.
Blood
80:2920-2924[Abstract/Free Full Text].
|
| 3.
|
Chandra, B.,
C. Louis, and T. Obrig.
1995.
Specific interaction of E. coli O157:H7-derived Shiga-like toxin 2 with human renal endothelial cells.
J. Infect. Dis.
172:1397-1401[Medline].
|
| 4.
|
Forsyth, K. D.,
A. C. Simpson,
M. M. Fitzpatrick,
T. M. Barratt, and R. J. Levinsky.
1989.
Neutrophil-mediated endothelial injury in haemolytic uremic syndrome.
Lancet
ii:411-414.
|
| 5.
|
Habib, R.,
M. Levy,
M. F. Gagnadoux, and M. Broyer.
1982.
Prognosis of the hemolytic uremic syndrome in children.
Adv. Nephrol.
11:99-128.
|
| 6.
|
Inward, C. D.,
J. Willias,
I. Chant,
J. Crocker,
D. V. Milford,
P. E. Rose, and C. M. Taylar.
1995.
Verotoxin-1 induces apoptosis in vero cells.
J. Infect.
30:213-218[Medline].
|
| 7.
|
Jackson, M. P.,
R. J. Neill,
A. D. O'Brien,
R. K. Holmes, and J. W. Newland.
1987.
Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin 1 and Shiga-like toxin 2 encoded by bacteriophages from Escherichia coli 933.
FEMS Microbiol. Lett.
44:109-114.
|
| 8.
|
Konowalchuk, J.,
J. I. Speirs, and S. Stavric.
1977.
Vero response to a cytotoxin of Escherichia coli.
Infect. Immun.
18:775-782[Abstract/Free Full Text].
|
| 9.
|
Lingwood, C. A.,
H. Law,
S. Richardson,
M. Petric,
J. L. Brunton,
S. D. Grandis, and M. A. Karmai.
1987.
Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro.
J. Biol. Chem.
262:8834-8843[Abstract/Free Full Text].
|
| 10.
|
Louise, C. B., and T. G. Obrig.
1991.
Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 , and tumor necrosis factor alpha on human vascular endothelial cells in vitro.
Infect. Immun.
59:4173-4179[Abstract/Free Full Text].
|
| 11.
|
Macleod, D. L., and C. L. Gyles.
1990.
Purification and characterization of an Escherichia coli Shiga-like toxin 2 variant.
Infect. Immun.
18:775-779.
|
| 12.
|
Mahan, J. D.,
C. McAllister, and M. Karmali.
1996.
Verotoxin-1 induction of apoptosis in human glomerular capillary endothelial cells (GCEC) in vitro is dependent on cytokines, cell confluence, and cell cycle.
J. Am. Soc. Nephrol.
7:1661.
|
| 13.
|
Morigi, M.,
G. Micheletti,
M. Figliuzzi,
B. Imberti,
M. A. Karmali,
A. Remuzzi, and C. Zoja.
1995.
Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions.
Blood
86:4553-4558[Abstract/Free Full Text].
|
| 14.
|
Nicoletti, I.,
G. Migliorati,
M. C. Pagliacci,
F. Grignani, and C. Riccardi.
1991.
A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.
J. Immunol. Methods
139:271-279[Medline].
|
| 15.
|
Ottonello, L.,
R. Gonella,
P. Dapino,
C. Sacchetti, and F. Dallegri.
1998.
Prostaglandin E2 inhibits apoptosis in human neutrophils: role of intracellular cyclic AMP levels.
Exp. Hematol.
26:895-902[Medline].
|
| 16.
|
Ramegowda, B., and V. L. Tesh.
1996.
Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity of Shiga-like toxin in human monocytes and monocytic cell lines.
Infect. Immun.
64:1173-1180[Abstract].
|
| 17.
|
Savill, J. S.,
A. H. Wyllie,
J. E. Henson,
M. J. Walport,
P. M. Heson, and C. Haslett.
1989.
Macrophage phagocytosis of aging neutrophils in inflammation.
J. Clin. Investig.
83:865-875.
|
| 18.
|
Setten, P. A. V.,
L. A. H. Monnerns,
R. G. G. Verstraten,
L. P. W. J. van den Heuvel, and V. W. M. van Hinsbergh.
1996.
Effects of verotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release.
Blood
88:174-183[Abstract/Free Full Text].
|
| 19.
|
Strockbine, N. A.,
L. R. M. Marques,
J. W. Newland,
H. W. Smith,
R. K. Holmes, and A. D. O'Brien.
1986.
Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities.
Infect. Immun.
53:135-140[Abstract/Free Full Text].
|
| 20.
|
Sweeney, J. F.,
P. K. Nguyen,
G. M. Omann, and D. B. Hinshaw.
1998.
Lipopolysaccharide protects polymorphonuclear leukocytes from apoptosis via tyrosine phosphorylation-dependent signal transduction pathways.
J. Surg. Res.
74:64-70[Medline].
|
| 21.
|
Taga, S.,
K. Carlier,
Z. Mishal,
C. Capoulade,
M. Mangeney,
Y. Lecluse,
D. Coulaud,
C. Tetaud,
L. L. Pritchard,
T. Tursz, and J. Wiels.
1997.
Intracellular signaling events in CD77-mediated apoptosis of Burkitt's lymphoma cells.
Blood
90:2757-2767[Abstract/Free Full Text].
|
| 22.
|
Tesh, V. L.,
B. Ramegowda, and J. E. Samuel.
1994.
Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages.
Infect. Immun.
62:5085-5094[Abstract/Free Full Text].
|
Infection and Immunity, November 1999, p. 6203-6205, Vol. 67, No. 11
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Griener, T. P., Mulvey, G. L., Marcato, P., Armstrong, G. D.
(2007). Differential binding of Shiga toxin 2 to human and murine neutrophils. J Med Microbiol
56: 1423-1430
[Abstract]
[Full Text]
-
Geelen, J. M., van der Velden, T. J. A. M., te Loo, D. M. W. M., Boerman, O. C., van den Heuvel, L. P. W. J., Monnens, L. A. H.
(2007). Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Nephrol Dial Transplant
22: 749-755
[Abstract]
[Full Text]
-
Flagler, M. J., Strasser, J. E., Chalk, C. L., Weiss, A. A.
(2007). Comparative Analysis of the Abilities of Shiga Toxins 1 and 2 To Bind to and Influence Neutrophil Apoptosis. Infect. Immun.
75: 760-765
[Abstract]
[Full Text]
-
Brigotti, M., Caprioli, A., Tozzi, A. E., Tazzari, P. L., Ricci, F., Conte, R., Carnicelli, D., Procaccino, M. A., Minelli, F., Ferretti, A. V. S., Paglialonga, F., Edefonti, A., Rizzoni, G.
(2006). Shiga Toxins Present in the Gut and in the Polymorphonuclear Leukocytes Circulating in the Blood of Children with Hemolytic-Uremic Syndrome. J. Clin. Microbiol.
44: 313-317
[Abstract]
[Full Text]
-
Harrison, L. M., van den Hoogen, C., van Haaften, W. C. E., Tesh, V. L.
(2005). Chemokine Expression in the Monocytic Cell Line THP-1 in Response to Purified Shiga Toxin 1 and/or Lipopolysaccharides. Infect. Immun.
73: 403-412
[Abstract]
[Full Text]
-
Blomgran, R., Zheng, L., Stendahl, O.
(2004). Uropathogenic Escherichia coli Triggers Oxygen-Dependent Apoptosis in Human Neutrophils through the Cooperative Effect of Type 1 Fimbriae and Lipopolysaccharide. Infect. Immun.
72: 4570-4578
[Abstract]
[Full Text]
-
Cameron, P., Bingham, D., Paul, A., Pavelka, M., Cameron, S., Rotondo, D., Plevin, R.
(2002). Essential Role for Verotoxin in Sustained Stress-Activated Protein Kinase and Nuclear Factor Kappa B Signaling, Stimulated by Escherichia coli O157:H7 in Vero Cells. Infect. Immun.
70: 5370-5380
[Abstract]
[Full Text]
-
TE LOO, D. M. W. M., HINSBERGH, V. W. M. V., HEUVEL, L. P. W. J. V. D., MONNENS, L. A. H.
(2001). Detection of Verocytotoxin Bound to Circulating Polymorphonuclear Leukocytes of Patients with Hemolytic Uremic Syndrome. J. Am. Soc. Nephrol.
12: 800-806
[Abstract]
[Full Text]
-
Wagner, P. L., Acheson, D. W. K., Waldor, M. K.
(2001). Human Neutrophils and Their Products Induce Shiga Toxin Production by Enterohemorrhagic Escherichia coli. Infect. Immun.
69: 1934-1937
[Abstract]
[Full Text]